ClinicalTrials.gg
CompletedNCT05915611Updated Oct 9, 2026

Combined Physical and Psychological Intervention in Carpal Tunnel Syndrome Patients With Nociplastic Pain

An interventional study of Standardized Carpal Tunnel Syndrome Rehabilitation and Psychologically Informed Pain-Management Program in Carpal Tunnel Syndrome and Pain, Chronic, sponsored by Ahram Canadian University. Completed at 1 site in Egypt. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Ahram Canadian University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 9, 2026Now CompletedStart date moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University — 5 open to participants now, 5 under way, none of them phase 3. Carpal Tunnel Syndrome · Ahram Canadian University.

Started
2023
with 9 others
No phase
3 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, this one is one of 10 that started in 2023, is one of 3 with no phase, and was the 7th registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

5 of the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, or all of them as a file.
02

Study summary

This randomized, assessor-blinded, parallel-group trial evaluated the effectiveness of adding a psychologically informed pain-management intervention to standardized physical rehabilitation in adults with electrodiagnostically confirmed carpal tunnel syndrome and coexisting mixed neuropathic-nociplastic pain features. A total of 178 participants were randomized in a 1:1 ratio. The active treatment period lasted 6 weeks, with follow-up through 12 weeks after randomization. The primary outcome was the Boston Carpal Tunnel Questionnaire-Symptom Severity Scale at 6 weeks.

Read the detailed description

This randomized, assessor-blinded, parallel-group trial evaluate whether adding a psychologically informed pain-management intervention to standardized physical rehabilitation improves carpal tunnel syndrome symptoms in adults with electrodiagnostically confirmed carpal tunnel syndrome and coexisting nociplastic pain features. A total of 178 participants will be randomized in a 1:1 ratio to receive either standardized physical rehabilitation plus a psychologically informed pain-management program or the same standardized physical rehabilitation plus attention-matched health education. The active treatment period will last 6 weeks, with follow-up at 12 weeks after randomization. The primary outcome will be the Boston Carpal Tunnel Questionnaire-Symptom Severity Scale at 6 weeks. Secondary outcomes will assess pain intensity, hand function, pain catastrophizing, kinesiophobia, upper-extremity disability, patient-perceived improvement, pain-processing characteristics, grip strength, and median-nerve electrophysiological measures.

03

Conditions studied

  • Carpal Tunnel Syndrome
  • Pain, Chronic
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 25-65 years with unilateral or bilateral carpal tunnel syndrome confirmed by compatible clinical findings and electrodiagnostic evidence of median neuropathy at the wrist.
  • CTS-related symptoms present for ≥3 months.
  • Mild-to-moderate CTS suitable for nonsurgical management.
  • Coexisting mixed neuropathic-nociplastic pain features according to a CTS-adapted IASP-aligned clinical algorithm.

Exclusion criteria

Exclusion Criteria:

  • Previous carpal tunnel release surgery on the study side.
  • Severe CTS with marked thenar weakness/atrophy, severe axonal loss, or other findings requiring prompt surgical evaluation.
  • Cervical radiculopathy or cervical myelopathy judged to better explain the upper-extremity symptoms.
  • Proximal median neuropathy or other peripheral entrapment neuropathy.
  • Generalized polyneuropathy.
  • Major shoulder, elbow, wrist, or hand disorder considered the dominant cause of symptoms or disability.
  • Recent injection or other invasive CTS treatment within a prespecified .
  • Concurrent structured CTS rehabilitation outside the study protocol.
  • Previous participation in a structured psychological pain-management program during the recent prespecified period.
  • Medical, cognitive, or communication limitations preventing safe participation or valid completion of study procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Standardized CTS Rehabilitation Plus Psychologically Informed Pain Management

    Participants will receive standardized physical rehabilitation for carpal tunnel syndrome together with a structured psychologically informed pain-management program for 6 weeks. Standardized rehabilitation will include night-time neutral-position wrist splinting, supervised flexor-tendon gliding and median-nerve neurodynamic exercises, education regarding symptom-provoking activities, and a standardized home-exercise program. Participants will additionally receive six individual psychologically informed pain-management sessions, approximately 40-45 minutes each, delivered once weekly.

    Other: Standardized Carpal Tunnel Syndrome Rehabilitation · Behavioral: Psychologically Informed Pain-Management Program

  • Active comparator
    Standardized CTS Rehabilitation Plus Attention-Matched Health Education

    Participants will receive the same standardized physical rehabilitation and home-exercise program as the experimental group for 6 weeks. In addition, participants will receive six individual attention-matched health-education sessions, approximately 40-45 minutes each, delivered once weekly. The health-education sessions will address general healthy lifestyle, sleep hygiene, physical activity, and hand health without including the specific psychologically informed pain-management components provided to the experimental group.

    Other: Standardized Carpal Tunnel Syndrome Rehabilitation · Behavioral: Attention-Matched Health Education

Interventions

  • OtherStandardized Carpal Tunnel Syndrome Rehabilitation

    Participants will receive a standardized 6-week physical rehabilitation program for carpal tunnel syndrome. Treatment will include night-time neutral-position wrist splinting, flexor-tendon gliding exercises, median-nerve neurodynamic exercises, education regarding activities that provoke symptoms, and a standardized home-exercise program. Supervised physical therapy will be provided twice weekly for 6 weeks, for a total of 12 supervised sessions. Participants will be instructed to perform the prescribed home exercises between supervised sessions.

  • BehavioralPsychologically Informed Pain-Management Program

    Participants will receive six individual psychologically informed pain-management sessions, approximately 40-45 minutes each, delivered once weekly over 6 weeks. The program will include pain neuroscience education, identification and modification of maladaptive pain beliefs, cognitive restructuring, strategies to reduce pain catastrophizing and fear of movement, graded exposure to feared upper-extremity activities, activity pacing, coping and self-management strategies, and relapse-prevention planning. The intervention will be delivered in addition to standardized CTS rehabilitation.

  • BehavioralAttention-Matched Health Education

    Participants will receive six individual health-education sessions, approximately 40-45 minutes each, delivered once weekly over 6 weeks. Sessions will be matched approximately to the experimental psychological intervention for therapist contact, frequency, and duration. Content will include general information regarding healthy lifestyle, sleep hygiene, physical activity, and general hand health. The sessions will not include pain neuroscience education, cognitive restructuring, pain-catastrophizing management, graded exposure, or other specific psychologically informed pain-management strategies.

06

What researchers measure

Primary outcomes

  1. Boston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS)

    Carpal tunnel syndrome symptom severity will be assessed using the 11-item Symptom Severity Scale of the Boston Carpal Tunnel Questionnaire. Each item is scored from 1 to 5, and the total scale score is calculated as the mean of the completed items, with higher scores indicating greater symptom severity. The primary endpoint is the BCTQ-SSS score at 6 weeks after randomization.

    Time frame: Baseline and 6 weeks after randomization.

Secondary outcomes

  1. Boston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS) Score at 12 Weeks

    Carpal tunnel syndrome symptom severity will be assessed using the 11-item Symptom Severity Scale of the Boston Carpal Tunnel Questionnaire (BCTQ-SSS). Each item is scored from 1 to 5. The scale score is calculated as the mean of the completed items and ranges from 1 to 5, with higher scores indicating greater symptom severity. The 12-week assessment will evaluate maintenance of the treatment effect after completion of the 6-week intervention period.

    Time frame: Baseline and 12 weeks after randomization.

  2. Pain catastrophizing using the Pain Catastrophizing Scale (PCS)

    Pain-related catastrophic thinking will be assessed using the 13-item Pain Catastrophizing Scale (PCS), which evaluates rumination, magnification, and helplessness related to pain. Each item is scored from 0 to 4, producing a total score ranging from 0 to 52. Higher scores indicate greater pain catastrophizing.

    Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks after randomization.

  3. Fear of movement using the Tampa Scale for Kinesiophobia (TSK)

    Fear of movement and pain-related movement avoidance will be assessed using the 11-item Tampa Scale for Kinesiophobia (TSK-11). Each item is scored on a 4-point scale, producing a total score ranging from 11 to 44. Higher scores indicate greater kinesiophobia.

    Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks after randomization.

  4. Grip strength measured using a hand dynamometer

    Maximum voluntary grip strength of the study hand will be measured using a calibrated hand dynamometer in a standardized seated position. Three trials will be performed with a prespecified rest interval between trials. The mean of the three trials, expressed in kilograms, will be used for analysis. Higher values indicate greater grip strength.

    Time frame: Baseline, 6 weeks, and 12 weeks after randomization.

  5. Numeric Pain Rating Scale for CTS-Related Hand and Wrist Pain

    Description: Average carpal tunnel syndrome-related hand and wrist pain during usual activities over the previous 7 days will be assessed using an 11-point Numeric Pain Rating Scale (NPRS), ranging from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: Baseline, 6 weeks, and 12 weeks after randomization.

  6. Boston Carpal Tunnel Questionnaire - Functional Status Scale (BCTQ-FSS)

    Carpal tunnel syndrome-related functional limitation will be assessed using the 8-item Functional Status Scale of the Boston Carpal Tunnel Questionnaire (BCTQ-FSS). Each item is scored from 1 to 5. The scale score is calculated as the mean of the completed items and ranges from 1 to 5, with higher scores indicating greater difficulty performing activities commonly affected by carpal tunnel syndrome.

    Time frame: Baseline, 6 weeks, and 12 weeks after randomization.

  7. Disabilities of the Arm, Shoulder and Hand (DASH) Score

    Upper-extremity symptoms and disability will be assessed using the 30-item Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The DASH score ranges from 0 to 100, with higher scores indicating greater upper-extremity disability and symptom severity.

    Time frame: Baseline, 6 weeks, and 12 weeks after randomization.

  8. Central Sensitization Inventory (CSI)

    Symptoms associated with central sensitization-related presentations will be assessed using Part A of the Central Sensitization Inventory (CSI). The 25 items are scored from 0 to 4 and summed to produce a total score ranging from 0 to 100. Higher scores indicate greater self-reported symptom burden associated with central sensitization-related presentations. The CSI will be used as a symptom-burden and phenotyping measure and not as a stand-alone diagnostic test for nociplastic pain.

    Time frame: Baseline, 6 weeks, and 12 weeks after randomization.

  9. Patient Global Impression of Change (PGIC)

    Participant-perceived overall change in carpal tunnel syndrome symptoms and functional status since the beginning of treatment will be assessed using the Patient Global Impression of Change (PGIC). Participants will rate their overall change using a 7-category scale ranging from "very much improved" to "very much worse." Responses will be analyzed as an ordinal measure of patient-perceived improvement or deterioration.

    Time frame: 6 weeks and 12 weeks after randomization.

Other outcomes

  1. Median Nerve Motor Distal Latency

    Median nerve motor distal latency will be measured using standardized nerve conduction testing, with stimulation of the median nerve and recording from the abductor pollicis brevis muscle. Distal motor latency will be recorded in milliseconds. Longer latency indicates greater slowing of median nerve motor conduction across the wrist.

    Time frame: Baseline and 12 weeks after randomization.

  2. Median Nerve Sensory Distal Latency

    Median nerve sensory distal latency will be measured using standardized sensory nerve conduction testing. Distal sensory latency will be recorded in milliseconds. Longer latency indicates greater slowing of median nerve sensory conduction across the wrist.

    Time frame: Baseline and 12 weeks after randomization.

  3. Median Nerve Compound Muscle Action Potential (CMAP) Amplitude

    Median nerve compound muscle action potential (CMAP) amplitude will be obtained during standardized motor nerve conduction testing and recorded in millivolts. CMAP amplitude provides an electrophysiological measure of motor axonal response.

    Time frame: Baseline and 12 weeks after randomization.

  4. median Nerve Sensory Nerve Action Potential (SNAP) Amplitude

    Median nerve sensory nerve action potential (SNAP) amplitude will be obtained during standardized sensory nerve conduction testing and recorded in microvolts. SNAP amplitude provides an electrophysiological measure of sensory axonal response.

    Time frame: Baseline and 12 weeks after randomization.

  5. Median Nerve Sensory Conduction Velocity

    Median nerve sensory conduction velocity will be calculated from standardized sensory nerve conduction testing and expressed in meters per second. Lower conduction velocity indicates greater slowing of median nerve sensory conduction.

    Time frame: Baseline and 12 weeks after randomization.

07

Study locations

1 site
  • Outpatient clinic of faculty of physical therapy, Ahram Canadian University
    Al Ḩayy Ath Thāmin, Giza Governorate 3221405, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in May 2026, 34 months.

Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's 34 months is above that.

Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Jun 2023 → Jul 2023, primary completion Sep 2024 → May 2026 and completion Sep 2024 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jun 23, 2023
StartActual
Jul 2, 2023was Jun 2023
Primary completionActual
May 11, 2026was Sep 2024
CompletionActual
Jun 22, 2026was Sep 2024
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 9, 2026
Sites
1 site added, 1 site removed
Show site
  • Outpatient clinic of faculty of physical therapy, Ahram Canadian University · Al Ḩayy Ath Thāmin, Egypt
Show 1 removed
  • Outpatient clinic of faculty of physical therapy, Ahram Canadian University · Al Ḩayy Ath Thāmin, Egypt
Oct 9, 2026
Start date
Jun 27, 2023→Jul 2, 2023 (actual)
Oct 9, 2026
Primary completion
Sep 27, 2024→May 11, 2026 (actual)
Oct 9, 2026
Study completion
Sep 27, 2024→Jun 22, 2026 (actual)
Oct 9, 2026
Enrollment
64 (estimated)→178 (actual)
Oct 9, 2026
Eligibility
Criteria largely rewritten (20 changes)
What changed in the criteria
Inclusion criteria
  • RemovedAdults aged 25-65 years
  • RemovedBoth sexes
  • RemovedDiagnosis of carpal tunnel syndrome based on clinical examination and nerve conduction studies
  • RemovedPresence of nociplastic pain as determined by the Central Sensitization Inventory (CSI) with a score ≥40
  • RemovedPositive tinel and phalen sign.
  • AddedAdults aged 25-65 years with unilateral or bilateral carpal tunnel syndrome confirmed by compatible clinical findings and electrodiagnostic evidence of median neuropathy at the wrist.
  • AddedCTS-related symptoms present for ≥3 months.
  • AddedMild-to-moderate CTS suitable for nonsurgical management.
  • AddedCoexisting mixed neuropathic-nociplastic pain features according to a CTS-adapted IASP-aligned clinical algorithm.
Exclusion criteria
  • EditedPrevious carpal tunnel release surgery on the study side.
  • RemovedOther musculoskeletal or neurological disorders affecting the upper extremity
  • AddedSevere CTS with marked thenar weakness/atrophy, severe axonal loss, or other findings requiring prompt surgical evaluation.
  • AddedCervical radiculopathy or cervical myelopathy judged to better explain the upper-extremity symptoms.
  • AddedProximal median neuropathy or other clinically important peripheral entrapment neuropathy.
  • AddedGeneralized polyneuropathy.
  • AddedMajor shoulder, elbow, wrist, or hand disorder considered the dominant cause of symptoms or disability.
  • AddedRecent corticosteroid injection or other invasive CTS treatment within a prespecified washout period.
  • AddedConcurrent structured CTS rehabilitation outside the study protocol.
  • AddedPrevious participation in a structured psychological pain-management program during the recent prespecified period.
  • AddedMedical, cognitive, or communication limitations preventing safe participation or valid completion of study procedures.
Oct 9, 2026
Interventions
Added Standardized Carpal Tunnel Syndrome Rehabilitation·Behavioral: Psychologically Informed Pain-Management Program·Behavioral: Attention-Matched Health Education; removed Combined physical and psychological intervention·Standard care. Arms added: Standardized CTS Rehabilitation Plus Psychologically Informed Pain Management·Standardized CTS Rehabilitation Plus Attention-Matched Health Education; arms removed: Intervention group·Control group
Oct 9, 2026
Primary outcomes
1 added, 4 removed
What changed in the outcomes
  • AddedBoston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS)Time frame: Baseline and 6 weeks after randomization.
  • RemovedPain intensity using the Numeric Pain Rating Scale (NPRS)Time frame: Changes in pain intensity at baseline, 6 weeks, 12 weeks.
  • RemovedFunctional ability using the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaireTime frame: Changes in Functional ability at baseline, 6 weeks, 12 weeks.
  • RemovedMedian nerve motor distal latencyTime frame: Changes in Median nerve motor distal latency at baseline, 6 weeks, 12 weeks.
  • RemovedMedian nerve sensory distal latencyTime frame: Changes in Median nerve sensory distal latency at baseline, 6 weeks, 12 weeks.
Oct 9, 2026
Secondary outcomes
3 time frame changed, 11 added, 3 description edited
What changed in the outcomes
  • AddedBoston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS) Score at 12 WeeksTime frame: Baseline and 12 weeks after randomization.
  • AddedNumeric Pain Rating Scale for CTS-Related Hand and Wrist PainTime frame: Baseline, 6 weeks, and 12 weeks after randomization.
  • AddedBoston Carpal Tunnel Questionnaire - Functional Status Scale (BCTQ-FSS)Time frame: Baseline, 6 weeks, and 12 weeks after randomization.
  • AddedDisabilities of the Arm, Shoulder and Hand (DASH) ScoreTime frame: Baseline, 6 weeks, and 12 weeks after randomization.
  • AddedCentral Sensitization Inventory (CSI)Time frame: Baseline, 6 weeks, and 12 weeks after randomization.
  • AddedPatient Global Impression of Change (PGIC)Time frame: 6 weeks and 12 weeks after randomization.
  • Time framePain catastrophizing using the Pain Catastrophizing Scale (PCS)Changes in Pain Catastrophizing Scale (PCS) at baseline, 6 weeks, 12 weeks. → Baseline, 3 weeks, 6 weeks, and 12 weeks after randomization.
  • Time frameFear of movement using the Tampa Scale for Kinesiophobia (TSK)Changes in Tampa Scale for Kinesiophobia (TSK) at baseline, 6 weeks, 12 weeks. → Baseline, 3 weeks, 6 weeks, and 12 weeks after randomization.
  • Time frameGrip strength measured using a hand dynamometerChanges in Grip strength at baseline, 6 weeks, 12 weeks. → Baseline, 6 weeks, and 12 weeks after randomization.
  • DescriptionFear of movement using the Tampa Scale for Kinesiophobia (TSK): how it is measured was reworded
  • DescriptionGrip strength measured using a hand dynamometer: how it is measured was reworded
  • DescriptionPain catastrophizing using the Pain Catastrophizing Scale (PCS): how it is measured was reworded
  • Addedother outcomeMedian Nerve Motor Distal LatencyTime frame: Baseline and 12 weeks after randomization.
  • Addedother outcomeMedian Nerve Sensory Distal LatencyTime frame: Baseline and 12 weeks after randomization.
  • Addedother outcomeMedian Nerve Compound Muscle Action Potential (CMAP) AmplitudeTime frame: Baseline and 12 weeks after randomization.
  • Addedother outcomemedian Nerve Sensory Nerve Action Potential (SNAP) AmplitudeTime frame: Baseline and 12 weeks after randomization.
  • Addedother outcomeMedian Nerve Sensory Conduction VelocityTime frame: Baseline and 12 weeks after randomization.
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Outpatient clinic of faculty of physical therapy, Ahram Canadian University · Al Ḩayy Ath Thāmin, Egypt
    Show 1 removed
    • Outpatient clinic of faculty of physical therapy, Ahram Canadian University · Al Ḩayy Ath Thāmin, Egypt
    Start date Jun 27, 2023→Jul 2, 2023 (now actual)
    Primary completion Sep 27, 2024→May 11, 2026 (now actual)
    Study completion Sep 27, 2024→Jun 22, 2026 (now actual)
    Enrollment 64 (estimated)→178 (actual)
    Eligibility Criteria largely rewritten (20 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedAdults aged 25-65 years
    • RemovedBoth sexes
    • RemovedDiagnosis of carpal tunnel syndrome based on clinical examination and nerve conduction studies
    • RemovedPresence of nociplastic pain as determined by the Central Sensitization Inventory (CSI) with a score ≥40
    • RemovedPositive tinel and phalen sign.
    • AddedAdults aged 25-65 years with unilateral or bilateral carpal tunnel syndrome confirmed by compatible clinical findings and electrodiagnostic evidence of median neuropathy at the wrist.
    • AddedCTS-related symptoms present for ≥3 months.
    • AddedMild-to-moderate CTS suitable for nonsurgical management.
    • AddedCoexisting mixed neuropathic-nociplastic pain features according to a CTS-adapted IASP-aligned clinical algorithm.
    Exclusion criteria
    • EditedPrevious carpal tunnel release surgery on the study side.
    • RemovedOther musculoskeletal or neurological disorders affecting the upper extremity
    • AddedSevere CTS with marked thenar weakness/atrophy, severe axonal loss, or other findings requiring prompt surgical evaluation.
    • AddedCervical radiculopathy or cervical myelopathy judged to better explain the upper-extremity symptoms.
    • AddedProximal median neuropathy or other clinically important peripheral entrapment neuropathy.
    • AddedGeneralized polyneuropathy.
    • AddedMajor shoulder, elbow, wrist, or hand disorder considered the dominant cause of symptoms or disability.
    • AddedRecent corticosteroid injection or other invasive CTS treatment within a prespecified washout period.
    • AddedConcurrent structured CTS rehabilitation outside the study protocol.
    • AddedPrevious participation in a structured psychological pain-management program during the recent prespecified period.
    • AddedMedical, cognitive, or communication limitations preventing safe participation or valid completion of study procedures.
    Primary outcomes 1 added, 4 removed
    What changed in the outcomes
    • AddedBoston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS)Time frame: Baseline and 6 weeks after randomization.
    • RemovedPain intensity using the Numeric Pain Rating Scale (NPRS)Time frame: Changes in pain intensity at baseline, 6 weeks, 12 weeks.
    • RemovedFunctional ability using the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaireTime frame: Changes in Functional ability at baseline, 6 weeks, 12 weeks.
    • RemovedMedian nerve motor distal latencyTime frame: Changes in Median nerve motor distal latency at baseline, 6 weeks, 12 weeks.
    • RemovedMedian nerve sensory distal latencyTime frame: Changes in Median nerve sensory distal latency at baseline, 6 weeks, 12 weeks.
    Secondary outcomes 3 time frame changed, 11 added, 3 description edited
    What changed in the outcomes
    • AddedBoston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS) Score at 12 WeeksTime frame: Baseline and 12 weeks after randomization.
    • AddedNumeric Pain Rating Scale for CTS-Related Hand and Wrist PainTime frame: Baseline, 6 weeks, and 12 weeks after randomization.
    • AddedBoston Carpal Tunnel Questionnaire - Functional Status Scale (BCTQ-FSS)Time frame: Baseline, 6 weeks, and 12 weeks after randomization.
    • AddedDisabilities of the Arm, Shoulder and Hand (DASH) ScoreTime frame: Baseline, 6 weeks, and 12 weeks after randomization.
    • AddedCentral Sensitization Inventory (CSI)Time frame: Baseline, 6 weeks, and 12 weeks after randomization.
    • AddedPatient Global Impression of Change (PGIC)Time frame: 6 weeks and 12 weeks after randomization.
    • Time framePain catastrophizing using the Pain Catastrophizing Scale (PCS)Changes in Pain Catastrophizing Scale (PCS) at baseline, 6 weeks, 12 weeks. → Baseline, 3 weeks, 6 weeks, and 12 weeks after randomization.
    • Time frameFear of movement using the Tampa Scale for Kinesiophobia (TSK)Changes in Tampa Scale for Kinesiophobia (TSK) at baseline, 6 weeks, 12 weeks. → Baseline, 3 weeks, 6 weeks, and 12 weeks after randomization.
    • Time frameGrip strength measured using a hand dynamometerChanges in Grip strength at baseline, 6 weeks, 12 weeks. → Baseline, 6 weeks, and 12 weeks after randomization.
    • DescriptionFear of movement using the Tampa Scale for Kinesiophobia (TSK): how it is measured was reworded
    • DescriptionGrip strength measured using a hand dynamometer: how it is measured was reworded
    • DescriptionPain catastrophizing using the Pain Catastrophizing Scale (PCS): how it is measured was reworded
    • Addedother outcomeMedian Nerve Motor Distal LatencyTime frame: Baseline and 12 weeks after randomization.
    • Addedother outcomeMedian Nerve Sensory Distal LatencyTime frame: Baseline and 12 weeks after randomization.
    • Addedother outcomeMedian Nerve Compound Muscle Action Potential (CMAP) AmplitudeTime frame: Baseline and 12 weeks after randomization.
    • Addedother outcomemedian Nerve Sensory Nerve Action Potential (SNAP) AmplitudeTime frame: Baseline and 12 weeks after randomization.
    • Addedother outcomeMedian Nerve Sensory Conduction VelocityTime frame: Baseline and 12 weeks after randomization.
    Interventions Added Standardized Carpal Tunnel Syndrome Rehabilitation·Behavioral: Psychologically Informed Pain-Management Program·Behavioral: Attention-Matched Health Education; removed Combined physical and psychological intervention·Standard care. Arms added: Standardized CTS Rehabilitation Plus Psychologically Informed Pain Management·Standardized CTS Rehabilitation Plus Attention-Matched Health Education; arms removed: Intervention group·Control group
    + 6 other changes: index terms, identifiers, verification date, description, design details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05915611
Lead sponsor
Ahram Canadian University
Responsible party
Mohamed Magdy ElMeligie (Lecturer of Physical Therapy and Director of Electromyography Lab, Ahram Canadian University) — Principal investigator
First posted
Jun 23, 2023
Start date
Jul 2, 2023
Primary completion
May 11, 2026
Completion
Jun 22, 2026
Last update
Oct 9, 2026

Study contacts

Amal Fawzy, Ph.d
study director · Faculty of Physical Therapy, Ahram Canadian University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion